FeNO measurement shows limited diagnostic performance for asthma in school-age children
This observational cohort study from the Swiss Paediatric Airway Cohort evaluated the diagnostic performance of fractional exhaled nitric oxide (FeNO) for asthma in 1,979 school-age children referred for suspected asthma. The reference standard was diagnosis by paediatric pulmonologists.
For asthma diagnosis, FeNO showed poor discrimination, with an AUC of 0.66 (95% CI 0.64-0.68). Asthma was diagnosed in 70% of the cohort. At a 25 ppb cut-off, sensitivity was 43% (95% CI 40-46) and specificity was 84% (95% CI 77-84). At a 35 ppb cut-off, sensitivity was 31% (95% CI 29-34) and specificity was 90% (95% CI 87-92). The positive predictive value at 35 ppb was 88%, and simulated at 30% prevalence was 57%.
Performance varied by subgroup. FeNO had no diagnostic value in non-sensitised children. In sensitised children with allergic rhinitis, the AUC was 0.59, while in those without rhinitis it was 0.68. Current inhaled corticosteroid use did not influence performance.
Safety and tolerability were not reported. Key limitations include that FeNO has limited diagnostic performance as a stand-alone test, performance varies by allergic sensitization and rhinitis status, and predictive values are affected by prevalence. Practice relevance is that FeNO has limited diagnostic performance for school-age asthma; interpretation should consider underlying prevalence and allergic characteristics.